How much Moderna will earn with the vaccine
Updates, forecasts and comments on the Modern American
Announcing fourth-quarter results yesterday, US pharmaceutical company Moderna expects to earn at least $ 19 billion from sales of its Covid vaccine in 2022, blowing analysts' earnings and revenue estimates, CNBC writes.
All the details.
HOW MUCH MODERN WILL EARN WITH THE VACCINE
The previous forecast estimated revenue of $ 17 billion for 2022 from sales of the Covid vaccine. Modern, however, has gone up to 19 billion.
“Moderna's shares – the article reads – rose by 11.4% in morning trading. The company's 2022 forecast for vaccine sales was $ 2 billion higher than its previous expectation. "
Stephane Bancel , CEO of Moderna, told analysts during a phone call about earnings that "the $ 19 billion reflects only signed purchase agreements and does not yet count potential US sales."
HOW MUCH HAS ALREADY EARNED
Moderna, CNBC reports, reported $ 4.9 billion in net profit for the fourth quarter. The company sold $ 17.7 billion of its vaccine in 2021, delivering 807 million doses worldwide. Moderna's revenue amounts to $ 18.5 billion for 2021.
BANCEL FORECASTS
Bancel, CNBC writes, declined to comment on the future price of the vaccine in the United States, although he expects it to rise as doses move into a normal private market. "We think that the price does not reflect the value of the vaccine from a pharmacoeconomic point of view," added Bancel.
THE MODERN PROJECTS
Moderna, meanwhile, is conducting a clinical trial for a recall that specifically targets the Omicron variant. However, it is unclear whether there will be strong demand from the public as new infections are dropping both in the United States and elsewhere in the world.
Additionally, the company said it is also developing a booster against both Omicron and other variants out there.
WHY A NEW VACCINE?
"We believe a preventive seasonal recall will be necessary," said Moderna president Stephen Hoge. "And we believe the continuing evolution of the virus will continue to put pressure on pre-existing immunity, whether it is naturally derived or vaccine-provided."
According to Paul Burton, Moderna's Chief Medical Officer, a recall that affects both Omicron and Delta will be needed in 2022.
"This is because Delta, as we know, is associated with a strong pathogenicity and Omicron, as we have seen, due to its transmissibility and infectivity, is also associated with a substantial morbidity and stress of health systems through the mass of cases", he Burton explained.
AS IF IT PASSES MODERN IN THE UNITED STATES
However, in the United States, the home of the company, the Food and Drug Administration (Fda) has not yet given authorization for the vaccine of Moderna under 18, which applied last summer for the 12- age group. 17 years.
In fact, the FDA is still evaluating data on the risk of myocarditis in adolescents. And just as Ema has authorized Moderna's Spikevax for the little ones, the company has made it known that in the United States it will not submit a new request to the American body to administer the vaccine in children aged 6 to 11 if it does not come first. approved in adolescents.
BEYOND COVID
In addition to the Covid projects, Moderna is conducting clinical trials for vaccines against common seasonal respiratory viruses. The company has launched a phase 3 trial of a respiratory syncytial virus vaccine and enrolled a phase 2 trial for an influenza vaccine.
Hoge said the company plans to move to a phase 3 trial for the flu vaccine this year. Moderna also plans to begin a phase 1 trial of a combined flu and Covid vaccine in 2022.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/economia/quanto-guadagnera-moderna-con-il-vaccino/ on Fri, 25 Feb 2022 11:11:26 +0000.